Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: Identification of a rare CD74-NRG1 translocation case

Medical Oncology

Volumn 31, Issue 7, 2014, Pages

  Gow, Chien Hung ^a   Wu, Shang Gin ^b   Chang, Yih Leong ^b,c   Shih, Jin Yuan ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CD74 NRG1; Lung; Mucinous adenocarcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 4; NEU DIFFERENTIATION FACTOR; B LYMPHOCYTE ANTIGEN; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; KRAS PROTEIN, HUMAN; NRG1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PULMONARY MUCINOUS ADENOCARCINOMA; RNA SEQUENCE; TAIWAN; TUMOR BIOPSY; WILD TYPE; ADENOCARCINOMA, MUCINOUS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE REPORT; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION RATE; NEUREGULIN-1; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAIWAN; TRANSLOCATION, GENETIC;

EID: 84901895449     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0034-4     Document Type: Article

References (19)

1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18(3):349-51. doi:10.1038/nm.2697.
2. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-81. doi:10.1038/nm.2658.
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-6. doi:10.1038/nature05945. (Pubitemid 47206930)
4. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375-7. doi:10.1038/nm.2644.
5. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469-72. doi:10.1038/nm.3352.
6. Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014. doi:10.1158/2159-8290.CD-13-0633.
7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8(5):381-5. doi:10.1513/pats.201107-042ST.
8. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32(4):924-30. doi:10.1183/09031936. 00167407.
9. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, et al. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013;82(3):420-5. doi:10.1016/j.lungcan.2013.10.005.
10. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009;131(4):478-89. doi:10.1309/AJCPH0TRMPXVZW2F.
11. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007;9(3):320-6. doi:10.2353/jmoldx.2007.060182. (Pubitemid 47305068)
12. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006;12(5):1647-53. doi:10.1158/1078-0432.CCR-05- 1981.
13. Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol. 2010;5(8):1197-200. doi:10.1097/JTO.0b013e3181e2a2bc.
14. Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T, et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 2011;117(18):4257-66. doi:10.1002/cncr.26010.
15. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. Frequency of driver mutations in lung adenocarcinoma from female neversmokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18(7):1947-53. doi:10.1158/1078-0432. CCR-11-2511.
16. Ichinokawa H, Ishii G, Nagai K, Kawase A, Yoshida J, Nishimura M, et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol. 2013; 44(12):2636-42. doi:10.1016/j.humpath.2013.05. 026.
17. Li Y, Pan Y, Wang R, Sun Y, Hu H, Shen X, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS ONE. 2013;8(7):e69016. doi:10.1371/journal.pone.0069016.
18. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013;79(1):8-13. doi:10.1016/j.lungcan.2012.09.018.
19. Shim SS, Han J. FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation. Ann Nucl Med. 2010;24(5):357-62. doi:10.1007/s12149-010-0358-x.